Dynavax Technologies Corporation (NASDAQ:DVAX) traded at a new 52-week high today of $13.79. So far today approximately 480,000 shares have been exchanged, as compared to an average 30-day volume of 2 million shares.
In the past 52 weeks, Dynavax Technologies Corporation share prices are bracketed by a low of $3.58 and a high of $13.79 and is now at $13.75, 284% above that low price.
Dynavax Technologies Corporation (NASDAQ:DVAX) has potential upside of 1,247.7% based on a current price of $13.75 and analysts’ consensus price target of $185.31.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its HEPLISAV-B product.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer